Boston, MA -- (SBWIRE) -- 11/21/2014 -- Huntington's disease is a progressive neurodegenerative disorder that can be inherited from one generation to another as an autosomal dominant trait. It arises due to genetically programmed degeneration of neurons in some parts of the brain such as basal ganglia and cerebral cortex. Basal ganglia plays an important role in coordinating movement while cerebral cortex regulates perception, thought, and memory. Degeneration of neurons leads to progressive cognitive impairment and dementia. People with Huntington's disease often develop chorea that causes involuntary muscle movements of hands, face, trunk, and feet. The behavioural disorders associated with the disease include depression, psychosis, and changes in personality. Other symptoms of the disease include speech impairment, anxiety, stress, and difficulty in swallowing. People suffering from Huntington's disease usually develop symptoms in their mid-30s and 40s. However, in few cases, disease symptoms appear in childhood or teens. The former case represents the adult-onset form of the disease, while the latter is the early-onset form. The early-onset form is associated with symptoms such as tremors, slow movements, and rigidity. Children with early-onset disease rarely live to adulthood. Currently, there is no approved treatment for Huntington's disease.

View Full Report Details and Table of Contents

TechNavio's analysts forecast the Global Huntington's Disease Therapeutics market to grow at a CAGR of 29.46 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Huntington's Disease Therapeutics market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of drugs approved for the treatment of symptoms of Huntington's disease.

TechNavio's report, the Global Huntington's Disease Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Huntington's Disease Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

- Americas
- APAC
- EMEA

Key Vendors

- Lundbeck
- Valeant Pharmaceuticals International

Other Prominent Vendors

- Auspex Pharmaceuticals
- GlaxoSmithKline
- Ipsen
- Omeros
- Palobiofarma
- Pfizer
- Prana Biotechnology
- Raptor Pharmaceutical
- Siena Biotech
- SOM Biotech
- Teva Pharmaceutical Industries

Market Driver

- Unmet Medical Needs
- For a full, detailed list, view our report

Market Challenge

- Poor Diagnosis Rates
- For a full, detailed list, view our report

Market Trend

- Novel Mechanisms Targeted by Pipeline Candidates
- For a full, detailed list, view our report

Key Questions Answered in this Report

- What will the market size be in 2018 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Companies Mentioned in this Report: Lundbeck, Valeant Pharmaceuticals International, Auspex Pharmaceuticals, GlaxoSmithKline, Ipsen, Omeros, Palobiofarma, Pfizer, Prana Biotechnology, Raptor Pharmaceutical, Siena Biotech, SOM Biotech, Teva Pharmaceutical Industries

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H2, 2014
- Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Global Clinical Trials Review, H2, 2013
- Alzheimer's Disease Global Clinical Trials Review, H1, 2014
- Fatty Liver Disease Global Clinical Trials Review, H2, 2014
- Peripheral Artery Occlusive Disease (PAOD) Global Clinical Trials Review, H2, 2014
- Occlusive Arterial Disease (OAD) Global Clinical Trials Review, H2, 2014
- Dementia Associated With Alzheimer's Disease Global Clinical Trials Review, H1, 2014
- Sickle Cell Disease Global Clinical Trials Review, H2, 2014
- Parkinson's Disease Global Clinical Trials Review, H2, 2013
- Fatty Liver Disease Global Clinical Trials Review, H2, 2013